NCT04096131

Brief Summary

To determine if cataract surgery may have an impact on the natural history of early DME (E-DME)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
143

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 9, 2019

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 19, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

January 28, 2020

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2021

Completed
Last Updated

August 16, 2021

Status Verified

August 1, 2021

Enrollment Period

10 months

First QC Date

September 9, 2019

Last Update Submit

August 13, 2021

Conditions

Keywords

diabetic macular edemacataractsurgery

Outcome Measures

Primary Outcomes (1)

  • Influence of cataract surgery on E-DME

    Changes in central subfield thickness (CST) and/or macular volume (MV) measured by SD-OCT in eyes with E-DME during the first 4 months after cataract surgery (Group 1) compared to eyes with the same condition but without any surgical intervention (Group 2). Eyes in both groups developing a "significant worsening" of E-DME, defined as an increase of at least 50 microns in central subfield thickness (CST) or 0.5 mm3 in macular volume (MV) measured by SD-OCT will be withdrawn from the study to receive adequate therapeutic intervention.

    4 months

Study Arms (2)

SURGERY

subjects with early DME undergoing cataract surgery

Procedure: cataract surgery

OBSERVATION

subjects with early DME

Interventions

phacoemulsification

SURGERY

Eligibility Criteria

Age55 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Study Groups GROUP 1: Eyes with E-DME scheduled for cataract surgery GROUP 2: Control Group. Eyes with E-DME and clear media, non-significant cataract, pseudophakic (Group 2a: phakic; Group 2b: pseudophakic) or eyes with cataract scheduled for surgery after the end of follow up. Gold candidate: patient with bilateral E-DME and cataract in at least one eye.

You may qualify if:

  • Eligible patients will be identified during the regular preoperative cataract examination. In the presence of a diabetic patient, an OCT scan will be performed (according to the protocol, see below).
  • Only eyes with E-DME will be eligible for the study.
  • Diabetic patients with bilateral E-DME and bilateral cataract. Both eyes will be enrolled: one eye will receive surgery at M4, the other at the end of follow up (M8) or later (gold candidate).
  • Diabetic patients with bilateral E-DME and cataract in just one eye (gold candidate). The eye with E-DME and no cataract may be already pseudophakic (surgery performed at least 18 months before) or with clear media.
  • Diabetic patients with E-DME and cataract in just one eye
  • Diabetic patients with cataract and no E-DME in the eye scheduled for surgery but E-DME in the other eye. Only the eye with E-DME will be enrolled.

You may not qualify if:

  • Past ocular surgery of any kind (except for cataract surgery) or ocular pathologies other than diabetic retinopathy.
  • Macular edema considered to be due to a cause other than diabetic macular edema.
  • OCT examination suggesting that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema. In the case of ERM, an OCT scan must be sent to the Coordinating Center for approval.
  • Any ocular pathology or ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema
  • History of any therapy (anti-VEGF treatment, focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids) for DME or diabetic retinopathy in the past 12 months.
  • History of YAG capsulotomy performed within two months before enrollment.
  • Aphakia.
  • Evidence of uncontrolled glaucoma.
  • Intraocular pressure must be \<25 mmHg, with no more than one topical glaucoma medication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ESASO Scientific Projects

Lugano, CH-6901, Switzerland

Location

MeSH Terms

Conditions

Cataract

Interventions

Cataract Extraction

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Refractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Scientific Studies Coordinator

Study Record Dates

First Submitted

September 9, 2019

First Posted

September 19, 2019

Study Start

January 28, 2020

Primary Completion

November 30, 2020

Study Completion

January 31, 2021

Last Updated

August 16, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations